Dianthus Therapeutics, Inc. (DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the ...

CLEVELAND, June 05, 2023 (GLOBE NEWSWIRE) -- NovelMed Therapeutics, Inc. announced today topline results from First-in-Human Phase I clinical trial of its complement blocker monoclonal anti-Properdin ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Researchers integrating transcriptomic and clinical profiling identified a monocyte-linked peripheral complement remodeling ...

ORLANDO, Fla.--(BUSINESS WIRE)--Hesperos Inc., pioneers of Human-on-a-Chip® in vitro systems, today announced the publication of a peer-reviewed article showing that a Human-on-a-Chip® (HoaC) ...

Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...

Annexon’s most closely watched near-term catalyst is a phase III geographic atrophy study expected to read out in the fourth quarter. Love said the trial is designed to replicate findings from the ...

Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease ...

Researchers find that a lipid damage signal both activates and limits the complement system during cell death, helping ...